A. Portron

发表

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus

S. Iida, Tomohisa Saito, D. Schwab, 2018, Drug Research.

Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Imipenem in Healthy Rats

W. Couet, J. Paquereau, A. Dupuis, 2001, Antimicrobial Agents and Chemotherapy.

Stanley Effect of Imipenem in Healthy Rats Modeling of the Electroencephalogram Pharmacokinetic-Pharmacodynamic

W. Couet, J. Paquereau, A. Dupuis, 2001 .

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

C. Hermans, V. Jiménez‐Yuste, S. Chebon, 2019, The Lancet. Haematology.

Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)

V. Jiménez‐Yuste, S. Chebon, M. Shima, 2017 .

A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.

C. Hofmann, Thijs MP van Iersel, P. Jordan, 2019, Clinical therapeutics.

Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).

N. Fotaki, N. Shah, H. Chokshi, 2012, Die Pharmazie.

賦形剤N-[8-(2-ヒドロキシベンゾイル)アミノ]カプリル酸ナトリウム含有イバンドロナートについて新規経口製剤選択のための第I相臨床試験

N. Fotaki, N. Shah, H. Chokshi, 2012 .

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 in people with type 2 diabetes mellitus

R. DiMarchi, N. Sarkar, C. Schmitt, 2017, Diabetes, obesity & metabolism.

A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans

Zoe Backholer, B. Lausecker, D. Schwab, 2013, Clinical Pharmacokinetics.

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

D. Hainzl, W. C. Stewart, D. Schwab, 2017, BMJ Open Ophthalmology.

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 after single subcutaneous administration in healthy subjects

R. DiMarchi, N. Sarkar, C. Schmitt, 2017, Diabetes, obesity & metabolism.

Clinical pharmacology of emicizumab for the treatment of hemophilia A

A. Kiialainen, N. Kotani, K. Yoneyama, 2023, Expert review of clinical pharmacology.

Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma

D. Norris, M. Björnsson, Suresh Vatakuti, 2023, CPT: pharmacometrics & systems pharmacology.